Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

NCT05200481 | Active Not Recruiting Phase 2 DMC

• 1 other identifier: IFCT-2101
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 29

Brief Summary

This is a phase II randomized, open-labelled, non-comparative multicenter study in which ALK+ NSCLC patients who are naïve of treatment for advanced disease will be randomized to receive brigatinib monotherapy (Arm A) or brigatinib and carboplatin-pemetrexed therapy (Arm B). An estimated 110 patients (55 in Arm A, 55 in Arm B) will be enrolled at approximately 30 centers. A safety phase will evaluate the safety of brigatinib with carboplatin and pemetrexed treatment combination (Arm B). The first twenty-six patients enrolled in Arm B will represent the population of the safety phase. Patients will be treated until they experience progressive disease, intolerable toxicity, or another discontinuation criterion is met. Continuation of brigatinib beyond progression is permitted, at the investigator's discretion, if there is evidence of continued clinical benefit. The null hypothesis is progression free survival at 12 months ≤ 69% for Arm B, which is considered not sufficiently clinically meaningful to warrant further study. The alternative hypothesis is that 86% or more of patients in Arm B would achieve progression free survival at 12 months.

Conditions

Non Small Cell Lung Cancer; ALK Gene Mutation

Keywords

IFCT; NCSLC; brigatinib; chemotherapy

Outcome Measures

Primary Outcomes (1)

• Progression Free Survival at 12 months, investigator assessment

  Time from enrollment to first observation of progression (RECIST1.1) or date of death (from any cause), determined by investigator assessment.

  12 months

Secondary Outcomes (13)

• Progression Free Survival (PFS) at 12 months, independent review

  12 months

• Overall Response Rate (ORR)

  At progression, after an average of 2 years

• Incidence, nature, and severity of adverse events

  From time of informed consent through treatment period and up to 30 days post last dose of study treatment (average of 2 years)

• Impact of ALK fusion detection in ctDNA on 12-months progression free survival

  12 months

• Impact of ALK fusion detection in ctDNA on overall response rate

  At progression, after an average of 2 years

Study Arms (2)

Brigatinib monotherapy Arm A

OTHER

Brigatinib 180mg QD (1 x 180mg tablet) until progression

Drug: Brigatinib 180 MG

Brigatinib Carboplatin-Pemetrexed combination therapy Arm B

EXPERIMENTAL

Brigatinib 180mg QD (1 x 180mg tablet) until progression + Carboplatin AUC of 5 mg/mL/min IV infusion every 3 weeks for 4 infusions + pemetrexed 500 mg/m² IV infusion every 3 weeks for 4 infusions

Drug: Brigatinib 180 MG; Drug: Carboplatin; Drug: Pemetrexed

Interventions

Brigatinib 180 MG DRUG

Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.

Also known as: ALUNBRIG

Brigatinib Carboplatin-Pemetrexed combination therapy Arm B; Brigatinib monotherapy Arm A

Carboplatin DRUG

Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.

Brigatinib Carboplatin-Pemetrexed combination therapy Arm B

Pemetrexed DRUG

Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.

Brigatinib Carboplatin-Pemetrexed combination therapy Arm B

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care. Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.
• Patients diagnosed with histologically or cytologically confirmed locally advanced not eligible to a local treatment or metastatic NSCLC (Stage IIIB, IIIC or IV accordingly to 8th classification TNM, UICC 2015).
• Patients are eligible for trial entry on the basis of locally determined ALK testing. ALK Immunohistochemistry (IHC) assay (3+ only), DNA-based or RNA-based next generation sequencing (NGS) assay, nCounter Nanostring assay or ALK FISH performed locally are accepted ALK testing assays. If ALK rearrangement diagnostic is performed using IHC and the result is + or 2+, a confirmation with a second method performed locally (DNA-based or RNA-based NGS assay, nCounter Nanostring assay or ALK FISH performed) is required.
• All Patients must have at least one measurable target lesion according to RECIST v1.1 per investigator assessment. The radiological assessment has to be done within the timelines indicated.
• Patients with asymptomatic and neurologically stable CNS metastases (including patients controlled with less than 10mg/day of methylprednisolone within the last week prior to study entry) will be eligible.
• Tumor Sample Requirement: sufficient tumor tissue for central analysis should be available (tumor block or a minimum of 10 unstained slides of 4 µm of analyzable tissue).
• Age ≥18 years.
• Life expectancy of at least 12 weeks, in the opinion of the Investigator.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
• Adequate Bone Marrow Function, including: Absolute Neutrophil Count (ANC) ≥1.5 x 109/L; Platelets ≥100 x 109/L; Hemoglobin ≥9 g/dL.
• Adequate Pancreatic Function, including: Serum lipase ≤3.0 ULN.
• Adequate Renal Function, including: Estimated creatinine clearance ≥45 mL/min as calculated using the standard method of the institution.
• Adequate Liver Function, including: Total serum bilirubin ≤1.5 x ULN (\<3.0 × ULN for patients with Gilbert syndrome); Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 x ULN; ≤5.0 x ULN if there is liver metastases involvement.
• Participants must have recovered from toxicities related to prior anticancer therapy to CTCAE Grade ≤ 1.
• Participants must have recovered from effects of any major surgery, or significant traumatic injury, at least 35 days before the first dose of treatment.

You may not qualify if:

• Previously received an investigational antineoplastic agent for NSCLC.
• Previously received any prior TKI, including ALK-targeted TKIs.
• Known molecular co-alteration i.e. activating EGFR/BRAF/KRAS/MET mutation and ROS1/RET/NTRK fusion.
• Previously received neo-adjuvant or adjuvant systemic chemotherapy or consolidation immunotherapy if completion of (neo) adjuvant/consolidation therapy occurred \<12 months prior to randomization.
• Patients who have leptomeningeal disease (LM) or carcinomatous meningitis (CM) according to MRI data and/or in case of documented cerebral spinal fluid (CSF) positive cytology.
• Spinal cord compression.
• Patients with symptomatic or neurologically instable CNS metastases.
• Major surgery within 30 days of study entry. Minor surgical procedures (e.g., port insertion, mediastinoscopy, surgical procedure for re-sampling) are not excluded, but sufficient time at investigator discretion should have passed for wound healing.
• Radiation therapy within 2 weeks of study entry. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry.
• Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness.
• Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: a) myocardial infarction within 6 months prior to the first dose of study drug; b) unstable angina within 6 months prior to the first dose of study drug; c) congestive heart failure within 6 months prior to the first dose of study drug; d) any history of ventricular arrhythmia; e) history of clinically significant atrial arrhythmia or clinically significant bradyarrhythmia as determined by the treating physician; f) cerebrovascular accident or transient ischemic attack within 6 months prior to the first dose of study drug.
• Have uncontrolled hypertension. Patients with hypertension should be under treatment on study entry to control blood pressure.
• History of grade 3 or 4 of interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, pulmonary fibrosis and radiation pneumonitis.
• Presence of interstitial fibrosis of any grade at baseline.
• Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Sponsors & Collaborators

• Intergroupe Francophone de Cancerologie Thoracique: lead

Study Sites (29)

CHU d'Angers

Angers, 49033, France

Location

CHU Besançon - Hôpital J. MINJOZ

Besançon, 25030, France

Location

Hôpital APHP Ambroise Paré

Boulogne, 92104, France

Location

Hospices Civils de Lyon - Hôpital Louis Pradel

Bron, 69677, France

Location

CHU Côte de Nacre

Caen, 14000, France

Location

Centre Jean Perrin

Clermont-Ferrand, 63011, France

Location

Centre Hospitalier Intercommunal de Créteil

Créteil, 94000, France

Location

Centre Georges-François Leclerc

Dijon, 21079, France

Location

Chu Grenoble

Grenoble, 38043, France

Location

Hôpital Calmette

Lille, 59037, France

Location

CHU Dupuytren

Limoges, 87042, France

Location

Centre Léon Bérard

Lyon, 69373, France

Location

Institut Paoli Calmettes

Marseille, 13273, France

Location

Hôpital Nord

Marseille, 13915, France

Location

Hôpital Arnaud de Villeneuve

Montpellier, 34295, France

Location

Centre Hospitalier

Mulhouse, 68070, France

Location

Hôpital Cochin

Paris, 75014, France

Location

Hôpital BICHAT

Paris, 75877, France

Location

Hôpital TENON

Paris, 75970, France

Location

Hôpital Haut-Lévèque

Pessac, 33604, France

Location

CHU Rennes - Hôpital Pontchaillou

Rennes, 35033, France

Location

Hôpital Charles Nicolle

Rouen, 76031, France

Location

Institut de Cancérologie de l'Ouest - René Gauducheau

Saint-Herblain, 44805, France

Location

Centre Hospitalier

Saint-Quentin, 02100, France

Location

Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

Location

HIA Sainte-Anne

Toulon, 83800, France

Location

Hôpital Larrey (CHU)

Toulouse, 31059, France

Location

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, 54511, France

Location

Centre Hospitalier de Villefranche-sur-Saône

Villefranche-sur-Saône, 69655, France

Location

Related Links

• IFCT website

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

brigatinib; Carboplatin; Pemetrexed

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Guanine; Hypoxanthines; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Dicarboxylic

Study Officials

• Michael DURUISSEAUX, Dr

  Hospices Civils de Lyon - Hôpital Louis Pradel

  PRINCIPAL INVESTIGATOR

• Aurélie SWALDUZ, Dr

  Centre Leon Berard

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Interventional, phase II, randomized, open-labelled, non-comparative multicenter study with two parallel arms

Study Record Dates

• First Submitted: January 7, 2022
• First Posted: January 20, 2022
• Study Start: May 18, 2022
• Primary Completion: September 1, 2025
• Study Completion (Estimated): October 1, 2028
• Last Updated: November 17, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

FR (29)